blood coagulation
Enable an agent to recognise blood coagulation, assess evidence of its progression and regulation, and identify justified observations or actions without treating a laboratory result as a diagnosis.
Research draft, second pass
A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.
recalled by Codex without web access - no source was read
Researched by: Codex
Purpose and description
Enable an agent to recognise blood coagulation, assess evidence of its progression and regulation, and identify justified observations or actions without treating a laboratory result as a diagnosis.
Blood coagulation is the regulated enzymatic process in which thrombin converts soluble fibrinogen into fibrin, which forms and stabilizes a blood clot in coordination with platelets and other components of haemostasis.
It can be Classify an observation as coagulation activity, a neighbouring haemostatic process or unresolved evidence.; Trace an episode from initiating stimulus through reaction surfaces to fibrin formation.; Compare serial results while checking specimen, reagent and treatment comparability.; Locate missing evidence needed to distinguish factor deficiency, inhibition and specimen interference.; Link coagulation observations to related clot, disease and treatment models.; Prepare evidence-qualified requests for further observation or expert review..
Distinguishing features
Identify evidence of coagulation-factor activity and fibrin production; platelet aggregation alone does not establish coagulation.
Distinguish the fibrin-forming process from haemostasis, whose endpoint is control of bleeding.
Distinguish coagulation activity from thrombosis: record whether an intravascular thrombus exists rather than assigning that diagnosis from activation alone.
Distinguish fibrin generation from fibrin breakdown, even when both occur during the same episode.
Separate coagulation in a collected specimen from coagulation in the organism by recording collection conditions and observation location.
Scope
+ Identification of coagulation episodes in vessels, tissues and collected blood
+ Initiating stimuli, reaction surfaces and coagulation-factor interactions
+ Thrombin generation, fibrin formation and fibrin stabilisation
+ Physiological inhibition and spatial containment of coagulation
+ Assay evidence, specimen conditions and uncertainty about process state
+ Effects of documented exposures or interventions on coagulation
- Primary platelet adhesion and aggregation except their contribution to coagulation
- Vascular constriction and the complete haemostatic response
- Fibrinolysis except its interface with fibrin persistence
- Blood-clot anatomy and embolus movement as independent objects or processes
- Full disease models for haemophilia, thrombosis and disseminated intravascular coagulation
- Individual treatment selection, medication dosing and prescribing
Characteristics
- Biological and experimental setting
- Species; in vivo, ex vivo or in vitro; whole blood, plasma or reconstituted system Determines which physiological interpretation an observation can support.
- Episode location
- Linked vessel, injury site, tissue compartment, specimen or experimental chamber Separates local activity from systemic inference and specimen artefact.
- Initiating stimulus
- Tissue-factor exposure, contact activation, assay reagent, mixed or unknown Identifies how the episode began and whether its mechanism represents physiological or experimental conditions.
- Observed process state
- Initiation, amplification, propagation, fibrin formation, stabilisation, inhibited or indeterminate; overlapping states permitted Supports a time-dependent account without imposing a strictly linear sequence.
- Factor availability and activity
- Factor-specific concentration or activity in reported units, with method and reference interval Separates measured quantity from functional contribution.
- Thrombin-generation profile
- Lag time in minutes, peak thrombin in nmol/L and endogenous thrombin potential in nmol·min/L, where supported by the assay Records reaction kinetics beyond a single clotting endpoint.
- Fibrin formation and stabilisation
- Not assessed, formation detected, stabilisation demonstrated or indeterminate; include evidence method Prevents visible clot formation from automatically establishing fibrin stabilisation.
- Clotting-assay result
- PT, aPTT or thrombin time in seconds; INR dimensionless when applicable; assay-specific reference interval Makes laboratory observations comparable only within justified methodological limits.
- Regulatory or treatment exposure
- Linked inhibitor, anticoagulant, replacement product or reversal intervention with exposure time Provides context for interpreting altered activity and serial results.
Also called
Where this came from
wikidata · CC0 1.0
Drafted structure
Bundle to layer to finding to question, as the second pass will find it: 6 bundles · 11 layers · 19 findings · 31 questions.
Episode and boundaries Establish what counts as the coagulation process being modelled and where it occurs.
A clot, a bleeding event and a prolonged assay time are different observations and must not become interchangeable instances.
Process identity
Separate coagulation from adjacent processes and its resulting material.
Fibrin-forming process
Record evidence for thrombin-mediated fibrin formation and distinguish it from the broader haemostatic response. [Physiological Haemostasis](https://www.ncbi.nlm.nih.gov/books/NBK534253/)
- What evidence identifies this observation as blood coagulation rather than platelet aggregation alone? definition
- Does the record describe an active process, its fibrin product or a laboratory proxy? boundary
Episode context
Anchor observations to a biological setting and time interval.
Site and observation window
Record species, anatomical or experimental compartment, trigger time and observation time.
- Did coagulation occur in a vessel, at an injury site or after sample collection? provenance
- What event defines the beginning of the episode, and which observation times are known? measurement
Initiation and reaction surfaces Represent the initiating stimulus and the surfaces supporting coagulation reactions.
The same factor measurements can have different implications depending on where reactions occur and how activation was initiated.
Activation route
Separate observed triggers from explanatory pathway labels.
Trigger and pathway framework
Record tissue-factor exposure, contact activation or experimental initiation, and identify whether the explanation uses cascade terminology or a cell-based account.
- What initiating stimulus was observed, added experimentally or merely inferred? provenance
- Are intrinsic and extrinsic pathway labels being used to explain an assay or an event in vivo? boundary
Surface localisation
Locate reaction complexes relative to cells and experimental phospholipids.
Surface-dependent factor function
Record reaction location as well as factor activity: cell-based experiments show that localisation affects a factor's haemostatic contribution. [Cellular interactions in hemostasis](https://pubmed.ncbi.nlm.nih.gov/8904166/)
- Which cells or supplied phospholipid surfaces support the recorded reactions? provenance
- What evidence supports transferring observations from this reaction surface to the biological setting of interest? boundary
Thrombin and fibrin production Track reaction progression and the formation of a stabilised fibrin network.
An agent must distinguish initiation, sustained enzymatic activity and the resulting fibrin structure.
Enzymatic progression
Describe factor participation and thrombin-generation kinetics.
Thrombin-generation evidence
Record measured or inferred thrombin generation, relevant factor activities and the evidence supporting the assigned process stage.
- Is thrombin generation directly measured, inferred from another endpoint or unassessed? measurement
- Which factor deficiencies, inhibitors or experimental conditions could explain the observed progression? boundary
Fibrin network
Distinguish fibrin production from subsequent stabilisation.
Formation and crosslinking
Separate fibrinogen conversion, fibrin assembly and factor XIII-mediated crosslinking. [Physiological Haemostasis](https://www.ncbi.nlm.nih.gov/books/NBK534253/)
- Which observation establishes fibrin formation rather than an unspecified change in sample consistency? measurement
- Has fibrin crosslinking been assessed, or is stabilisation being inferred from clot appearance? measurement
Containment and net persistence Represent limits on coagulation activity and the interface with fibrin removal.
Fibrin present at one moment does not by itself reveal the rates of its generation, inhibition or breakdown.
Coagulation inhibition
Record endogenous inhibitory mechanisms and the spatial extent of activation.
Regulatory restraint
Capture evidence concerning antithrombin, the protein C system, tissue factor pathway inhibitor and localisation of coagulation. [Physiological Haemostasis](https://www.ncbi.nlm.nih.gov/books/NBK534253/)
- Which endogenous inhibitory mechanisms were assessed, and by what method? measurement
- What evidence distinguishes local coagulation activity from activation across multiple sites? boundary
Formation-removal interface
Link fibrin production to independently represented breakdown and persistence.
Net fibrin observation
Record whether evidence concerns new fibrin production, accumulated fibrin or degradation, and preserve uncertainty when these cannot be separated.
- Does the observation measure fibrin formation, fibrin degradation or their combined outcome? measurement
- Which aspects of the episode require a linked fibrinolysis or thrombus model? boundary
Assays and action evidence Connect laboratory observations and documented interventions to defensible interpretations.
Coagulation measurements depend on specimen preparation, assay design and exposure history; interpretation must retain those dependencies.
Assay validity
Describe the specimen, activation method and measured endpoint before interpreting a result.
Endpoint and preanalytics
Record collection conditions, sample handling, reagents, instruments and reference intervals. PT, aPTT and thrombin time measure time to fibrin formation under different activation conditions. [Coagulation Tests](https://ncbi.nlm.nih.gov/books/NBK265/)
- What specimen, reagent and endpoint produced this result, and what reference interval applies? provenance
- Were tube filling, processing delay, contamination and specimen clotting assessed before interpretation? measurement
- What conclusions about coagulation in vivo remain unsupported by this assay? boundary
Intervention and review
Relate changes to exposure timing and identify justified next observations.
Exposure-aware next step
Link anticoagulant exposure, factor replacement or reversal to serial observations without assigning causation solely from temporal association.
- Which relevant exposures occurred before sampling, and how certain are their timing and identity? provenance
- What additional evidence would distinguish a biological change from assay interference or specimen error? action
- Does the available evidence justify a repeat observation, a linked disease assessment or expert review? action
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Check these first
Recalled without web access and unsourced; every item is a lead to verify.
- This describes the physiological process in humans and other mammals, not generic coagulation of colloids; details differ across animal groups.
- The traditional intrinsic, extrinsic and common pathways are useful laboratory teaching categories, but physiological coagulation is better understood as interacting reactions on cellular surfaces.
- Recalled reference intervals are illustrative, not treatment targets or diagnostic thresholds; verify local assay ranges and the precise WHO document before formal publication.
- Which of these check these first hold for the sense of blood coagulation this model covers, and on what evidence? provenance
Kinds and varieties
Recalled without web access and unsourced; every item is a lead to verify.
- Physiological coagulation contributing to haemostasis after vascular injury
- Pathological coagulation contributing to thrombosis
- Coagulation outside the body in collected blood
- Which of these kinds and varieties hold for the sense of blood coagulation this model covers, and on what evidence? provenance
Identifiers and schemes
Recalled without web access and unsourced; every item is a lead to verify.
- Gene Ontology - GO:0007596 - Biological process term for blood coagulation.
- Which of these identifiers and schemes hold for the sense of blood coagulation this model covers, and on what evidence? provenance
Standards and regulation
Recalled without web access and unsourced; every item is a lead to verify.
- World Health Organization guidance and international reference preparations support thromboplastin calibration and standardization of prothrombin-time results using the international normalized ratio (INR).
- Which of these standards and regulation hold for the sense of blood coagulation this model covers, and on what evidence? provenance
Real-world use
Recalled without web access and unsourced; every item is a lead to verify.
- Stopping bleeding and stabilizing the initial platelet plug after vascular injury
- Evaluating bleeding disorders and deficiencies of coagulation factors
- Monitoring selected anticoagulant treatments with appropriate laboratory assays
- Assessing coagulation during major bleeding, surgery and transfusion
- Developing haemostatic treatments and antithrombotic medicines
- Which of these real-world use hold for the sense of blood coagulation this model covers, and on what evidence? provenance
Typical measurements
Recalled without web access and unsourced; every item is a lead to verify.
- Prothrombin time (PT) - Approximately 11-14 in healthy adults; reagent and laboratory dependent - s
- Activated partial thromboplastin time (aPTT) - Approximately 25-35 in healthy adults; reagent and laboratory dependent - s
- International normalized ratio (INR) - Approximately 0.8-1.2 in people not receiving vitamin K antagonists - dimensionless
- Plasma fibrinogen concentration - Approximately 2-4 in healthy adults; method and population dependent - g/L
- Which of these typical measurements hold for the sense of blood coagulation this model covers, and on what evidence? provenance
Failure modes and hazards
Recalled without web access and unsourced; every item is a lead to verify.
- Insufficient coagulation from factor deficiencies or inhibitors can cause prolonged or spontaneous bleeding.
- Excessive or misplaced coagulation can produce thrombosis, obstruct blood flow and contribute to embolism.
- Disseminated intravascular coagulation can combine widespread microvascular clotting with consumption of platelets and coagulation factors, producing both organ injury and bleeding.
- Anticoagulant treatment can cause bleeding; inadequate anticoagulation in an indicated setting can leave thrombotic risk insufficiently controlled.
- Improper blood collection or handling can produce misleading coagulation-test results.
- Which of these failure modes and hazards hold for the sense of blood coagulation this model covers, and on what evidence? provenance
Regional variation
Recalled without web access and unsourced; every item is a lead to verify.
- Laboratories and jurisdictions differ in assay reagents, reporting conventions and reference intervals; INR provides specific standardization for vitamin K antagonist monitoring.
- Which of these regional variation hold for the sense of blood coagulation this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Recalled without web access and unsourced; every item is a lead to verify.
- Haemostasis - Haemostasis is the broader control of bleeding, including vascular responses, platelet activity and coagulation.
- Platelet aggregation - Platelet aggregation joins platelets into a plug; coagulation generates the fibrin that reinforces it.
- Thrombosis - Thrombosis is pathological clot formation within the circulation; coagulation is a process that also serves normal haemostasis.
- Fibrinolysis - Fibrinolysis breaks down fibrin, whereas coagulation generates and stabilizes it.
- Blood clot - A blood clot is the resulting material structure; blood coagulation is the process producing its fibrin component.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of blood coagulation this model covers, and on what evidence? provenance
What the second pass must settle
- Which nonhuman species must the registry entry cover, and which mechanisms require species-specific extensions?
- Which operational criteria should distinguish initiation, propagation and containment across in vivo observations and different laboratory platforms?
- How should contact activation and inflammation-associated coagulation be represented across injury, artificial surfaces and pathological settings?
- Which assay-specific evidence is sufficient to infer impaired or excessive coagulation in a defined context, and where must the state remain indeterminate?
- Does an existing Vercy world model already own this process, requiring this registry entry to link to it instead of producing a separate publication?